Strategic agreement to leverage MEDIAN's advanced lesion management
system (LMS) software applications and associated clinical trial imaging
services for early, late-stage or post-approval oncology clinical trials
To improve the assessment of how cancer patients are responding to
investigational therapies in clinical trials, MEDIAN Technologies
(Paris:ALMDT) today announced a strategic agreement with Quintiles to
offer advanced integrated image services to biopharmaceutical customers
The agreement with Median, a leading services provider for image
interpretation and management in oncology clinical trials, is designed
to further strengthen Quintiles' full range of services to accelerate
oncology drug development. With Quintiles, the world's leading
biopharmaceutical services provider, as its partner, Median can extend
the reach of its technologies in the clinical development field to
benefit customers globally.
"This collaboration will result in better quality of data, increased
awareness for biopharma for go/no-go decisions along the drug
development stages, and ultimately more robust regulatory submission to
health agencies," said MEDIAN Chief Executive Officer Fredrik Brag.
Under terms of the agreement, Quintiles will have the potential to be
awarded warrants, which if exercised could amount to up to a 15% equity
position in the company.
Anne Pilling, Vice President, Quintiles Oncology Therapeutic Delivery
Unit, said: "This partnership complements Quintiles' current
portfolio of imaging solutions and provides further proof of our
commitment to provide biopharma and healthcare service providers with
the tools, expertise and services needed to increase productivity and
better the lives of patients."
Images are essential in clinical trials and are used at all steps of
cancer care, from patient diagnosis to monitoring. In clinical trials,
they provide a critical indication of patient response to treatment of
new candidate drug and are used as input for new drug and therapeutic
schemes registration. MEDIAN's solution addresses two critical imaging
challenges: data variability amongst readers and efficient management of
the imaging data workflow.
About Quintiles: Quintiles is the only fully integrated
biopharmaceutical services company offering clinical,
solutions worldwide. The Quintiles network of more than 20,000 engaged
professionals in 60 countries works with an unwavering commitment to
patients, safety and ethics. Quintiles helps biopharmaceutical companies
navigate risk and seize opportunities in an environment where change is
constant. For more information, please visit www.quintiles.com
About MEDIAN Technologies: Based in Sophia Antipolis, MEDIAN was
founded in 2002 by Fredrik Brag (Current CEO), Gérard Milhiet and Arnaud
Butzbach. The company has a staff of 40, over half of whom work in R&D,
and has a subsidiary in the USA.
MEDIAN Technologies offers solutions and services for diagnosing and
monitoring cancer patients for clinical trials market in oncology, its
priority market, and the patient care market. MEDIAN a collaborated with
institutes at the cutting edge of medical imaging, among which the
French National Institute for Computer Science and Control (INRIA),
Chicago University and the Swiss Federal Institute of Technology in
Lausanne, Switzerland (EPFL).
MEDIAN Technologies has been present in the market since 2007 through
direct and indirect sales of its LMS solutions and alliances with
specialist cancer centers in Europe and the USA.
For more information on MEDIAN, please visit: www.mediantechnologies.com
Quintiles Media Relations
919 993 2066
+1 919 998 2000
Fredrik Brag, CEO
+33 492 906 582
+ 33 664 189 959
+ 33 142 688
+ 33 1 42 68 86 41
+ 33 1 56 88 11 14